대한부인종양학회

최신 논문

총 게시글 : 156

Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer 2024-03-29 VIEW : 9
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, singlearm, phase 2 trial 2024-03-29 VIEW : 5
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial 2024-03-29 VIEW : 7
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study 2024-03-29 VIEW : 9
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients – An international pooled analysis of three ESGO accredited centres 2024-03-29 VIEW : 5
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement 2024-03-29 VIEW : 12
Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy 2023-12-26 VIEW : 41
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer 2023-12-26 VIEW : 18
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial 2023-12-26 VIEW : 54
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer 2023-12-26 VIEW : 9
Reducing Unnecessary Oophorectomies for Benign Ovarian Neoplasms in Pediatric Patients 2023-12-26 VIEW : 4
Safety and antitumour activity of cadonilimab, an anti- PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial 2023-12-26 VIEW : 3
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial 2023-12-26 VIEW : 12
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer SubgroupAnalysesfromtheKEYNOTE-826RandomizedClinicalTrial 2023-12-26 VIEW : 9
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update 2023-09-19 VIEW : 52

1
2
3
4
5
6
7
8
9
10
11